Analysts Offer Insights on Healthcare Companies: Ampliphi Biosciences (AMEX: APHB) and Nabriva (NASDAQ: NBRV)

By Ryan Adsit

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ampliphi Biosciences (AMEX: APHB) and Nabriva (NASDAQ: NBRV) with bullish sentiments.

Ampliphi Biosciences (AMEX: APHB)

Ampliphi Biosciences (AMEX: APHB) received a Buy rating and a $5 price target from H.C. Wainwright analyst Joseph Pantginis today. The company’s shares closed on Friday at $0.78, close to its 52-week high of $17.90.

According to TipRanks.com, Pantginis is ranked 0 out of 5 stars with an average return of -19.9% and a 29.5% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Applied Genetic Technologies, and ImmunoCellular Therapeutics.

Ampliphi Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $5.

Nabriva (NASDAQ: NBRV)

In a report released today, Ed Arce from H.C. Wainwright reiterated a Buy rating on Nabriva (NASDAQ: NBRV), with a price target of $18. The company’s shares closed on Friday at $8.16, close to its 52-week high of $11.79.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 24.1% and a 47.5% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics Inc, and Sucampo Pharmaceuticals.

Nabriva has an analyst consensus of Strong Buy, with a price target consensus of $16.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.